For the quarter ending 2025-09-30, TLSIW made $11,566K in revenue. -$41,274K in net income. Net profit margin of -356.86%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Revenue | 11,566 | 11,213 | ||
| Cost of goods sold | 1,906 | 1,802 | ||
| Gross profit | 9,660 | 9,411 | ||
| Research and development | 5,176 | 3,923 | ||
| Sales and marketing | 6,839 | 7,163 | ||
| General and administrative | 6,659 | 5,657 | ||
| Loss from operations | -9,014 | -7,332 | ||
| Interest income | 170 | 134 | ||
| Interest expense | 1,460 | 1,423 | ||
| Change in fair value of sepa, warrant and revenue base redemption liabilities | -2,932 | -330 | ||
| Change in fair value of contingent earnout liability | -2,524 | -700 | ||
| Other expense, net | -94 | -40 | ||
| Loss before income taxes | -10,806 | -8,291 | ||
| Income tax benefit (expense) | 5 | -3 | ||
| Net loss | -10,811 | -8,288 | ||
| Series a preferred stock conversion inducement | 18,516 | - | ||
| Deemed dividend related to seriesa preferred stock conversion | 11,947 | - | ||
| Undeclared dividends on series a preferred stock | 0 | 714 | ||
| Net loss attributable to common stockholders | -41,274 | -9,002 | ||
| Net loss per common share, basic (in dollars per share) | -0.96 | -0.27 | ||
| Net loss per common share, diluted (in dollars per share) | -0.96 | -0.27 | ||
| Weighted average common shares outstanding, basic (in shares) | 43,057,632 | 32,899,297 | ||
| Weighted average common shares outstanding, diluted (in shares) | 43,057,632 | 32,899,297 | ||
TriSalus Life Sciences, Inc. (TLSIW)
TriSalus Life Sciences, Inc. (TLSIW)